Case Report: Serial stereotactic radiotherapy in lieu of systemic therapy change for oligoprogressive breast cancer: eight courses to 17 metastases
- Journal Title
- Frontiers in Oncology
- Publication Type
- Case report
- Abstract
- Stereotactic ablative body radiotherapy (SABR) is emerging as a strategy for treating oligoprogressive disease in lieu of changing systemic therapy. We report the case of a patient with oligoprogressive breast cancer who received seven sequential rounds of SABR and one course of stereotactic radiosurgery to 17 metastases over 5 years, delaying a change in systemic therapy on eight occasions. The patient's age, performance status, and treatment preferences guided this unique treatment journey, emphasising quality of life. In limited trials, SABR has not demonstrated improvement in overall survival. Nevertheless, early evidence, including this case of oligoprogression, supports its role in delaying systemic therapy.
- Publisher
- Frontiers
- Keywords
- breast cancer; metastatic; oligoprogressive; radiotherapy; stereotactic ablative body radiotherapy (SABR); stereotactic body radiation therapy (SBRT); stereotactic radiosurgery (SRS)
- Department(s)
- Radiation Oncology
- Publisher's Version
- https://doi.org/10.3389/fonc.2026.1641876
- Open Access at Publisher's Site
https://doi.org/10.3389/fonc.2026.1641876- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-04-28 11:41:18
Last Modified: 2026-04-28 11:41:44